A carregar...
SUN-249 Growth Hormone Utilization By US Youth: Trends as Insurance Pushes Back after FDA-Approved Expansion
In 2003 US FDA approved growth hormone (GH) treatment for idiopathic short stature (ISS), expanding potential eligibility for GH treatment from 1:3500 children with GH deficiency to the shortest 1.2% of the US population, at a potential estimated national cost of $40 billion. In response, over the l...
Na minha lista:
| Publicado no: | J Endocr Soc |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Endocrine Society
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6553063/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-SUN-249 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|